Literature DB >> 15567461

Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines.

Shane A Olwill1, Hugh McGlynn, William S Gilmore, H Denis Alexander.   

Abstract

INTRODUCTION: Acute promyelocytic leukaemia (APL) (M3) is associated with both a characteristic t(15;17) and severe bleeding diathesis caused by disseminated intravascular coagulation (DIC) and/or hyperfibrinolysis. It has been suggested that annexin II, a coreceptor for tissue plasminogen activator (t-PA) and plasminogen (PLG), is overexpressed on the surface of promyelocytes, leading to an increased fibrinolytic potential.
MATERIALS AND METHODS: This study examined the level of annexin II cell surface and mRNA expression in a range of acute myeloid leukaemia (AML) cell lines. The evidence that annexin II levels are higher in APL would lend support to the hypothesis that the bleeding disorder seen in APL is caused by hyperfibrinolysis.
RESULTS: Cell surface annexin II was found to be expressed at higher levels on NB4 (promyelocytic) cells than on either KG1a (early myeloid) or HL60 (myelocytic) cells. However, even higher levels were found on U937 and MM6 (histo-monocytic) and HEL (erythroid) cells (p<0.01). MM6 cells showed a threefold increase in annexin II mRNA compared to any of the other cell lines.
CONCLUSIONS: These findings do not fully support the concept of the coagulopathy associated with APL being caused by hyperfibrinolysis alone. Further investigations are required to identify the significance of annexin II expression and regulation in leukaemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15567461     DOI: 10.1016/j.thromres.2004.07.014

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  The role of annexin A2 in tumorigenesis and cancer progression.

Authors:  Noor A Lokman; Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Cancer Microenviron       Date:  2011-03-05

2.  Annexin A2-S100A10 heterotetramer is upregulated by PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia.

Authors:  Dan Huang; Yan Yang; Jian Sun; Xiaorong Dong; Jiao Wang; Hongchen Liu; Chengquan Lu; Xueyu Chen; Jing Shao; Jinsong Yan
Journal:  Front Med       Date:  2017-07-08       Impact factor: 4.592

3.  Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo.

Authors:  Zurina Romay-Penabad; Maria Guadalupe Montiel-Manzano; Tuya Shilagard; Elizabeth Papalardo; Gracie Vargas; Arun B Deora; Michael Wang; Andrew T Jacovina; Ethel Garcia-Latorre; Elba Reyes-Maldonado; Katherine A Hajjar; Silvia S Pierangeli
Journal:  Blood       Date:  2009-07-23       Impact factor: 22.113

4.  Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

Authors:  Gabriela Cesarman-Maus; Nina P Ríos-Luna; Arunkumar B Deora; Bihui Huang; Rosario Villa; Maria del Carmen Cravioto; Donato Alarcón-Segovia; Jorge Sánchez-Guerrero; Katherine A Hajjar
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

5.  Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding.

Authors:  Clifford C Taggart; Sally-Ann Cryan; Sinead Weldon; Aileen Gibbons; Catherine M Greene; Emer Kelly; Teck Boon Low; Shane J O'neill; Noel G McElvaney
Journal:  J Exp Med       Date:  2005-12-13       Impact factor: 14.307

6.  Characterization of plasminogen binding to NB4 promyelocytic cells using monoclonal antibodies against receptor-induced binding sites in cell-bound plasminogen.

Authors:  Mercè Jardí; Pere Fàbregas; María Sagarra-Tió; María José Pérez-Lucena; Jordi Félez
Journal:  J Biomed Biotechnol       Date:  2012-10-14

7.  Three are better than one: plasminogen receptors as cancer theranostic targets.

Authors:  Patrizia Ceruti; Moitza Principe; Michela Capello; Paola Cappello; Francesco Novelli
Journal:  Exp Hematol Oncol       Date:  2013-04-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.